Aastrom Biosciences is a leader in the development of autologous cellular therapies for use in the treatment of severe, chronic cardiovascular diseases. The company has developed a proprietary technology that expands populations of early stem and progenitor cells derived from a sample of a patient's own bone marrow. Its tissue repair cell-based therapies are in late-stage clinical testing and have now been used in over 375 patients.
Aastrom is dedicated to developing first-in-class treatments for dilated cardiomyopathy and critical limb ischemia-critical cardiovascular diseases that currently have limited or no treatment options.
